The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas
Open accessAbstract
Purpose: To evaluate the potential benefit of continuous daily dosing sunitinib in patients with advanced nongastrointestinal stromal tumor (GIST) sarcomas. Patients and Methods: A total of 53 patients with advanced non-GIST soft tissue sarcomas received sunitinib 37.5 mg daily. Primary end point was Response Evaluation Criteria in Solid Tumors defined response. Secondary end points were stable disease at 16 and 24 weeks. [ 18 F]-fluorodeoxyglucose positron emission tomography was performed on a subset of 24 patients at baseline and after 10 to 14 days of therapy. Results: Forty-eight patients were eligible for response. One patient (desmoplastic round cell tumor [DSRCT]) achieved a confirmed partial response (PR) and remained on study for 56 weeks. Ten patients (20%) achieved stable disease for at least 16 weeks. Metabolic PR was seen in 10 (47%) of 21 of patients. Metabolic stable disease was seen in 11 (52%) of 21. There were no unexpected toxicities observed. Conclusion: Sunitinib demonstrated notable evidence of metabolic response in several patients with non-GIST sarcoma. The relevance of disease control observed in subtypes with an indolent natural history is unknown, however, the durable disease control observed in DSRCT, solitary fibrous tumor, and giant cell tumor of bone suggests that future evaluation of sunitinib in these subtypes may be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Pathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K., & Mertens, F. (2002) · Lund University Publications (Lund University) · Cited by 4,467
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Self-citationDemetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607
Self-citationPathology and genetics of tumours of soft tissue and bone
Fletcher, C. D. �., Unni, K. K., & Mertens, F. (2002) · Medical Entomology and Zoology · Cited by 2,073
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Choi, H., Charnsangavej, C., Faria, S. C., Macapinlac, H. A., Burgess, M. A., Patel, S. R., Chen, L. L., Podoloff, D. A., & Benjamin, R. S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,520
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Self-citationSunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Cancer: Principles and Practice of Oncology
CLAUDINO, W. M., & BIGANZOLI, L. (2007) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2006.00680.x · Cited by 855
Molecular basis for sunitinib efficacy and future clinical development
Faivre, S., Demetri, G., Sargent, W., & Raymond, E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2380 · Cited by 721
Self-citationStroobants, S., Goeminne, J., Seegers, M., Dimitrijevic, S., Dupont, P., Nuyts, J., Martens, M., van den Borne, B., Cole, P., Sciot, R., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00073-x · Cited by 526
McArthur, G. A., Demetri, G. D., van Oosterom, A., Heinrich, M. C., Debiec-Rychter, M., Corless, C. L., Nikolova, Z., Dimitrijevic, S., & Fletcher, J. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.088 · Cited by 482
Self-citationMechanisms of sarcoma development
Helman, L. J., & Meltzer, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1168 · Cited by 460
World Health Organization Classification of Tumors
Tavassoli, F. A. (2003) · Medical Entomology and Zoology · Cited by 376
Rubin, B. P., Schuetze, S. M., Eary, J. F., Norwood, T. H., Mirza, S. K., Conrad, E. U., & Bruckner, J. D. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.027 · Cited by 364
Gene expression profiling of human sarcomas: insights into sarcoma biology.
Baird, K., Davis, S., Antonescu, C. R., Harper, U. L., Walker, R. L., Chen, Y., Glatfelter, A. A., Duray, P. H., & Meltzer, P. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1699 · Cited by 353 · cited 1×
“Gene expression profiling has revealed that a number of sarcomas have high levels of expression of tyrosine kinases or receptor tyrosine kinases, making them potential targets for therapy with tyrosine kinase inhibitors.(14,15) Sarcoma subtypes included in group A included vascular connective tissue neoplasms, includi…”
BackgroundHeinrich, M. C., McArthur, G. A., Demetri, G. D., Joensuu, H., Bono, P., Herrmann, R., Hirte, H., Cresta, S., Koslin, D. B., Corless, C. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0717 · Cited by 318
Self-citationCasali, P. G., Messina, A., Stacchiotti, S., Tamborini, E., Crippa, F., Gronchi, A., Orlandi, R., Ripamonti, C., Spreafico, C., Bertieri, R., et al. (2004) · Cancer · doi:10.1002/cncr.20618 · Cited by 268
Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor
Khakoo, A. Y., Kassiotis, C. M., Tannir, N., Plana, J. C., Halushka, M., Bickford, C., Trent, J., Champion, J. C., Durand, J., & Lenihan, D. J. (2008) · Cancer · doi:10.1002/cncr.23460 · Cited by 252
Maki, R. G., Awan, R. A., Dixon, R. H., Jhanwar, S., & Antonescu, C. R. (2002) · International Journal of Cancer · doi:10.1002/ijc.10535 · Cited by 250
Self-citationResponse of extraabdominal desmoid tumors to therapy with imatinib mesylate
Mace, J., Sybil Biermann, J., Sondak, V., McGinn, C., Hayes, C., Thomas, D., & Baker, L. (2002) · Cancer · doi:10.1002/cncr.11029 · Cited by 193
Holdsworth, C. H., Badawi, R. D., Manola, J. B., Kijewski, M. F., Israel, D. A., Demetri, G. D., & Van den Abbeele, A. D. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.07.2496 · Cited by 167
Self-citationKollmannsberger, C., Soulières, D., Wong, R. P. W., Scalera, A., Gaspo, R., & Bjarnason, G. A. (2012) · Canadian Urological Association Journal · doi:10.5489/cuaj.67 · Cited by 150
Tamborini, E., Miselli, F., Negri, T., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1584 · Cited by 148
Genetic aberrations in soft tissue leiomyosarcoma
Yang, J., Du, X., Chen, K., Ylipää, A., Lazar, A. J., Trent, J. C., Lev, D. C., Pollock, R. E., Hao, X., Hunt, K. K., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.013 · Cited by 110
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma
Grossmann, M., Premaratne, E., Desai, J., & Davis, I. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03253.x · Cited by 109
Hlubocky, F. J., Ratain, M. J., Wen, M., & Daugherty, C. K. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9800 · Cited by 102
Choi, H. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0055-4 · Cited by 100
Rare case of hemangiopericytoma responds to sunitinib
Mulamalla, K., Truskinovsky, A. M., & Dudek, A. Z. (2008) · Translational research · doi:10.1016/j.trsl.2007.12.007 · Cited by 38
Signal transduction pathways in sarcoma as targets for therapeutic intervention
Tuveson, D. A., & Fletcher, J. A. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200107000-00007 · Cited by 37
Cited by
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Self-citationYoung, R. J., Brown, N. J., Reed, M. W., Hughes, D., & Woll, P. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70023-1 · Cited by 962
Chordoma: current concepts, management, and future directions
Walcott, B. P., Nahed, B. V., Mohyeldin, A., Coumans, J.-V., Kahle, K. T., & Ferreira, M. J. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70337-0 · Cited by 769
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., Ganjoo, K. N., George, S., Gonzalez, R. J., Heslin, M. J., Kane, J. M., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0025 · Cited by 736
Self-citationStacchiotti, S., & Sommer, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71190-8 · Cited by 501
Metadata
- Authors
- George, S., Merriam, P., Maki, R. G., Van den Abbeele, A. D., Yap, J. T., Akhurst, T., Harmon, D. C., Bhuchar, G., O'Mara, M. M., D'Adamo, D. R., Morgan, J., Schwartz, G. K., Wagner, A. J., Butrynski, J. E., Demetri, G. D., & Keohan, M. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-01
- Volume
- 27
- Issue
- 19
- Pages
- 3154-3160
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170583701
- Cited by
- 321
- References
- 32
- FWCI
- 21.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.